BCR and Autoimmunity: These findings indicate that LY3541860 will be able to inhibit B cell activation caused by a variety of signals in the context of human autoimmunity, which is important since it has been demonstrated that BCR-, innate-, and cytokine/CD40-induced signaling all play roles in the development of autoimmunity.